Cited by 555Computational Drug Discovery MethodsProtein Degradation and InhibitorsHeterocyclic Compound Synthesis and Bioactivity

The DOI matches its Crossref record; 251 of the 251 references it cites were found in a registry or an index.

Polypharmacology by Design: A Medicinal Chemist’s Perspective on Multitargeting Compounds

Proschak, Ewgenij, Stark, Holger, Merk, Daniel·2019·Journal of Medicinal Chemistry

DOI 10.1021/acs.jmedchem.8b00760

Open this paper in CoChat — free account

Abstract

Multitargeting compounds comprising activity on more than a single biological target have gained remarkable relevance in drug discovery owing to the complexity of multifactorial diseases such as cancer, inflammation, or the metabolic syndrome. Polypharmacological drug profiles can produce additive or synergistic effects while reducing side effects and significantly contribute to the high therapeutic success of indispensable drugs such as aspirin. While their identification has long been the result of serendipity, medicinal chemistry now tends to design polypharmacology. Modern in vitro pharmacological methods and chemical probes allow a systematic search for rational target combinations and recent innovations in computational technologies, crystallography, or fragment-based design equip multitarget compound development with valuable tools. In this Perspective, we analyze the relevance of multiple ligands in drug discovery and the versatile toolbox to design polypharmacology. We conclude that despite some characteristic challenges remaining unresolved, designed polypharmacology holds enormous potential to secure future therapeutic innovation.

Integrity signals

Registry

Crossref · 10.1021/acs.jmedchem.8b00760

Cites

251 of 251 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors
Takahashi, K., & Yamanaka, S. (2006) · Cell · doi:10.1016/j.cell.2006.07.024 · Cited by 26,673
Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (1997) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(96)00423-1 · Cited by 11,484
Extended-Connectivity Fingerprints
Rogers, D. O. W., & Hahn, M. (2010) · Journal of Chemical Information and Modeling · doi:10.1021/ci100050t · Cited by 7,925
The new frontier of genome engineering with CRISPR-Cas9
Doudna, J. A., & Charpentier, E. (2014) · Science · doi:10.1126/science.1258096 · Cited by 7,062
Network pharmacology: the next paradigm in drug discovery
Hopkins, A. L. (2008) · Nature Chemical Biology · doi:10.1038/nchembio.118 · Cited by 4,622
Monitoring Drug Target Engagement in Cells and Tissues Using the Cellular Thermal Shift Assay
Molina, D. M., Jafari, R., Ignatushchenko, M., Seki, T., Larsson, E. A., Dan, C., Sreekumar, L., Cao, Y., & Nordlund, P. (2013) · Science · doi:10.1126/science.1233606 · Cited by 2,261
LigandScout: 3-D Pharmacophores Derived from Protein-Bound Ligands and Their Use as Virtual Screening Filters
Wolber, G., & Langer, T. (2004) · Journal of Chemical Information and Modeling · doi:10.1021/ci049885e · Cited by 1,989
The ChEMBL bioactivity database: an update
Bento, A. P., Gaulton, A., Hersey, A., Bellis, L. J., Chambers, J. K., Davies, M., Krüger, F. A., Light, Y., Mak, L., McGlinchey, S., et al. (2013) · Nucleic Acids Research · doi:10.1093/nar/gkt1031 · Cited by 1,520
Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework
Cook, D., Brown, D., Alexander, R., March, R., Morgan, P., Satterthwaite, G., & Pangalos, M. N. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4309 · Cited by 1,344
Concepts and applications of molecular similarity
Johnson, M. A., & Maggiora, G. M. (1990) · Wiley eBooks · Cited by 1,301
Designed Multiple Ligands. An Emerging Drug Discovery Paradigm
Morphy, R., & Ranković, Z. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm058225d · Cited by 1,255
Tracking cancer drugs in living cells by thermal profiling of the proteome
Savitski, M. M., Reinhard, F. B. M., Franken, H., Werner, T., Savitski, M. F., Eberhard, D., Molina, D. M., Jafari, R., Dovega, R. B., Klaeger, S., et al. (2014) · Science · doi:10.1126/science.1255784 · Cited by 1,187
Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia
Roth, B. L., Sheffler, D. J., & Kroeze, W. K. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1346 · Cited by 1,155
Multi-target-Directed Ligands To Combat Neurodegenerative Diseases
Cavalli, A., Bolognesi, M. L., Minarini, A., Rosini, M., Tumiatti, V., Recanatini, M., & Melchiorre, C. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm7009364 · Cited by 1,152
Polypharmacology: Challenges and Opportunities in Drug Discovery: Miniperspective
Anighoro, A., Bajorath, J., & Rastelli, G. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm5006463 · Cited by 1,131
Target identification using drug affinity responsive target stability (DARTS)
Lomenick, B., Hao, R., Jonai, N., Chin, R., Aghajan, M., Warburton, S., Wang, J., Wu, R. P., Gómez, F., Loo, J. A., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0910040106 · Cited by 1,130
Multi-target therapeutics: when the whole is greater than the sum of the parts
Zimmermann, G. R., Lehár, J., & Keith, C. T. (2007) · Drug Discovery Today · doi:10.1016/j.drudis.2006.11.008 · Cited by 1,105
Identification of Telmisartan as a Unique Angiotensin II Receptor Antagonist With Selective PPARγ–Modulating Activity
Benson, S. C., Pershadsingh, H. A., Ho, C. I., Chittiboyina, A. G., Desai, P. V., Pravenec, M., Qi, N., Wang, J., Avery, M. A., & Kurtz, T. W. (2004) · Hypertension · doi:10.1161/01.hyp.0000123072.34629.57 · Cited by 1,076
Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors
Bantscheff, M., Eberhard, D., Abraham, Y., Bastuck, S., Böesche, M., Hobson, S., Mathieson, T., Perrin, J., Raida, M., Rau, C., et al. (2007) · Nature Biotechnology · doi:10.1038/nbt1328 · Cited by 1,036
Molecular Complexity and Its Impact on the Probability of Finding Leads for Drug Discovery
Hann, M. M., Leach, A. R., & Harper, G. (2001) · Journal of Chemical Information and Computer Sciences · doi:10.1021/ci000403i · Cited by 904
Pharmacophore modeling and applications in drug discovery: challenges and recent advances
Yang, S. (2010) · Drug Discovery Today · doi:10.1016/j.drudis.2010.03.013 · Cited by 902
The promise and peril of chemical probes
Arrowsmith, C. H., Audia, J. E., Austin, C., Baell, J., Bennett, J., Blagg, J., Bountra, C., Brennan, P. E., Brown, P. J., Bunnage, M. E., et al. (2015) · Nature Chemical Biology · doi:10.1038/nchembio.1867 · Cited by 839
Automated design of ligands to polypharmacological profiles
Besnard, J., Ruda, G. F., Setola, V., Abecassis, K., Rodriguiz, R. M., Huang, X.-P., Norval, S., Sassano, M. F., Shin, A. I., Webster, L. A., et al. (2012) · Nature · doi:10.1038/nature11691 · Cited by 832
Do Structurally Similar Molecules Have Similar Biological Activity?
Martin, Y. C., Kofron, J. L., & Traphagen, L. M. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm020155c · Cited by 806
Antibody-drug conjugates: recent advances in conjugation and linker chemistries
Tsuchikama, K., & An, Z. (2016) · Protein & Cell · doi:10.1007/s13238-016-0323-0 · Cited by 798
The pharmacology of statins
Sirtori, C. R. (2014) · Pharmacological Research · doi:10.1016/j.phrs.2014.03.002 · Cited by 753
A perspective on multi‐target drug discovery and design for complex diseases
Ramsay, R. R., Popović-Nikolić, M. R., Nikolic, K. M., Uliassi, E., & Bolognesi, M. L. (2018) · Clinical and Translational Medicine · doi:10.1186/s40169-017-0181-2 · Cited by 751
From magic bullets to designed multiple ligands
Morphy, R., Kay, C., & Ranković, Z. (2004) · Drug Discovery Today · doi:10.1016/s1359-6446(04)03163-0 · Cited by 738
Principles in the design of ligand-targeted cancer therapeutics and imaging agents
Srinivasarao, M., Galliford, C. V., & Low, P. S. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4519 · Cited by 687
PubChem BioAssay: 2017 update
Wang, Y., Bryant, S. H., Cheng, T., Wang, J., Gindulytė, A., Shoemaker, B. A., Thiessen, P. A., He, S., & Zhang, J. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw1118 · Cited by 675
Targeting the cancer kinome through polypharmacology
Knight, Z. A., Lin, H., & Shokat, K. M. (2010) · Nature reviews. Cancer · doi:10.1038/nrc2787 · Cited by 674
DeepSynergy: predicting anti-cancer drug synergy with Deep Learning
Preuer, K., Lewis, R. P. I., Hochreiter, S., Bender, A., Bulusu, K. C., & Klambauer, G. (2017) · Bioinformatics · doi:10.1093/bioinformatics/btx806 · Cited by 668
Thermal proteome profiling for unbiased identification of direct and indirect drug targets using multiplexed quantitative mass spectrometry
Franken, H., Mathieson, T., Childs, D., Sweetman, G. M. A., Werner, T., Tögel, I., Doce, C., Gade, S., Bantscheff, M., Drewes, G., et al. (2015) · Nature Protocols · doi:10.1038/nprot.2015.101 · Cited by 651
Cathepsin B-Labile Dipeptide Linkers for Lysosomal Release of Doxorubicin from Internalizing Immunoconjugates: Model Studies of Enzymatic Drug Release and Antigen-Specific In Vitro Anticancer Activity
Dubowchik, G. M., Firestone, R. A., Padilla, L., Willner, D., Hofstead, S. J., Mosure, K. W., Knipe, J. O., Lasch, S. J., & Trail, P. A. (2002) · Bioconjugate Chemistry · doi:10.1021/bc025536j · Cited by 560
High-throughput crystallography for lead discovery in drug design
Blundell, T. L., Jhoti, H., & Abell, C. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd706 · Cited by 538
Shifting from the single to the multitarget paradigm in drug discovery
Medina‐Franco, J. L., Giulianotti, M. A., Welmaker, G. S., & Houghten, R. A. (2013) · Drug Discovery Today · doi:10.1016/j.drudis.2013.01.008 · Cited by 498
Polypharmacology – Foe or Friend?
Peters, J. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400856t · Cited by 485
Target Identification for Small Bioactive Molecules: Finding the Needle in the Haystack
Ziegler, S., Pries, V., Hedberg, C., & Waldmann, H. (2013) · Angewandte Chemie International Edition · doi:10.1002/anie.201208749 · Cited by 473
Can we rationally design promiscuous drugs?
HOPKINS, A., MASON, J., & OVERINGTON, J. (2006) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2006.01.013 · Cited by 469
Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases
Apsel, B., Blair, J. A., González, B., Nazif, T. M., Feldman, M. E., Aizenstein, B., Hoffman, R., Williams, R. L., Shokat, K. M., & Knight, Z. A. (2008) · Nature Chemical Biology · doi:10.1038/nchembio.117 · Cited by 460
Multi-target pharmacology: possibilities and limitations of the “skeleton key approach” from a medicinal chemist perspective
Talevi, A. (2015) · Frontiers in Pharmacology · doi:10.3389/fphar.2015.00205 · Cited by 401
Prospects for new antibiotics: a molecule-centered perspective
Walsh, C. T., & Wencewicz, T. A. (2013) · The Journal of Antibiotics · doi:10.1038/ja.2013.49 · Cited by 385
De Novo Design of Bioactive Small Molecules by Artificial Intelligence
Merk, D., Friedrich, L., Grisoni, F., & Schneider, G. (2018) · Molecular Informatics · doi:10.1002/minf.201700153 · Cited by 373
Self-citation
Natural compounds and combination therapy in colorectal cancer treatment
Rejhova, A., Opattová, A., Čumová, A., Slíva, D., & Vodička, P. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.12.039 · Cited by 367
Dual kinase-bromodomain inhibitors for rationally designed polypharmacology
Ciceri, P., Müller, S., O’Mahony, A., Fedorov, O., Filippakopoulos, P., Hunt, J. P., Lasater, E. A., Pallares, G., Picaud, S., Wells, C. D., et al. (2014) · Nature Chemical Biology · doi:10.1038/nchembio.1471 · Cited by 345
Chemical genetic discovery of targets and anti-targets for cancer polypharmacology
Dar, A. C., Das, T. K., Shokat, K. M., & Cagan, R. L. (2012) · Nature · doi:10.1038/nature11127 · Cited by 337
Dual or multi-targeting inhibitors: The next generation anticancer agents
Raghavendra, N. M., Pingili, D., Kadasi, S., Mettu, A., & Prasad, S. V. U. M. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.10.021 · Cited by 333
Designing Smart Polymer Conjugates for Controlled Release of Payloads
Seidi, F., Jenjob, R., & Crespy, D. (2018) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00006 · Cited by 330
Drug repositioning and repurposing: terminology and definitions in literature
Langedijk, J., Mantel-Teeuwisse, A. K., Slijkerman, D. S., & Schutjens, M.-H. D. B. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2015.05.001 · Cited by 327
Molecule-pharmacophore superpositioning and pattern matching in computational drug design
Wolber, G., Seidel, T., Bendix, F., & Langer, T. (2007) · Drug Discovery Today · doi:10.1016/j.drudis.2007.09.007 · Cited by 315
Multi-targeting by monotherapeutic antibacterials
Silver, L. L. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2202 · Cited by 311
Thermal proteome profiling monitors ligand interactions with cellular membrane proteins
Reinhard, F. B. M., Eberhard, D., Werner, T., Franken, H., Childs, D., Doce, C., Savitski, M. F., Huber, W. K., Bantscheff, M., Savitski, M. M., et al. (2015) · Nature Methods · doi:10.1038/nmeth.3652 · Cited by 310
In silico repositioning of approved drugs for rare and neglected diseases
Ekins, S., Williams, A. J., Krasowski, M. D., & Freundlich, J. S. (2011) · Drug Discovery Today · doi:10.1016/j.drudis.2011.02.016 · Cited by 294
From in silico target prediction to multi-target drug design: Current databases, methods and applications
Koutsoukas, A., Simms, B., Kirchmair, J., Bond, P. J., Whitmore, A. V., Zimmer, S., Young, M. P., Jenkins, J. L., Glick, M., Glen, R. C., et al. (2011) · Journal of Proteomics · doi:10.1016/j.jprot.2011.05.011 · Cited by 291
A history of antipsychotic drug development
Shen, W. W. (1999) · Comprehensive Psychiatry · doi:10.1016/s0010-440x(99)90082-2 · Cited by 284
NLLSS: Predicting Synergistic Drug Combinations Based on Semi-supervised Learning
Chen, X., Ren, B., Chen, M., Wang, Q., Zhang, L., & Yan, G. (2016) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1004975 · Cited by 284
Designing multi-targeted agents: An emerging anticancer drug discovery paradigm
Fu, R.-G., Sun, Y., Sheng, W., & Liao, D. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.05.016 · Cited by 270
Designing Multiple Ligands – Medicinal Chemistry Strategies and Challenges
Morphy, R., & Ranković, Z. (2009) · Current Pharmaceutical Design · doi:10.2174/138161209787315594 · Cited by 262
Multi-Target Drugs: The Trend of Drug Research and Development
Lu, J., Pan, W., Yuanjia, H., & Wang, Y. (2012) · PLoS ONE · doi:10.1371/journal.pone.0040262 · Cited by 259
Cancer biomarkers: selecting the right drug for the right patient
Kelloff, G. J., & Sigman, C. C. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3651 · Cited by 256
Network pharmacology of cancer: From understanding of complex interactomes to the design of multi-target specific therapeutics from nature
Poornima, P., Kumar, J. D., Zhao, Q., Blunder, M., & Efferth, T. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.06.018 · Cited by 254
DOGS: Reaction-Driven de novo Design of Bioactive Compounds
Hartenfeller, M., Zettl, H., Walter, M., Rupp, M., Reisen, F., Proschak, E., Weggen, S., Stark, H., & Schneider, G. (2012) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1002380 · Cited by 251
Self-citation
Sideromycins: tools and antibiotics
Braun, V., Pramanik, A., Gwinner, T., Köberle, M., & Bohn, E. (2009) · BioMetals · doi:10.1007/s10534-008-9199-7 · Cited by 237
Antipsychotic drugs for patients with schizophrenia and predominant or prominent negative symptoms: a systematic review and meta-analysis
Krause, M., Zhu, Y., Huhn, M., Schneider‐Thoma, J., Bighelli, I., Nikolakopoulou, A., & Leucht, S. (2018) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-018-0869-3 · Cited by 234
Methods for High-throughput Drug Combination Screening and Synergy Scoring
He, L., Kulesskiy, E., Saarela, J., Turunen, L., Wennerberg, K., Aittokallio, T., & Tang, J. (2018) · Methods in Molecular Biology · doi:10.1007/978-1-4939-7493-1_17 · Cited by 232
In silico methods to address polypharmacology: current status, applications and future perspectives
Lavecchia, A., & Cerchia, C. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2015.12.007 · Cited by 230
Comparative Assessment of Scoring Functions on an Updated Benchmark: 1. Compilation of the Test Set
Li, Y., Liu, Z., Li, J., Han, L., Liu, J., Zhao, Z., & Wang, R. (2014) · Journal of Chemical Information and Modeling · doi:10.1021/ci500080q · Cited by 221
Multifunctional compounds: Smart molecules for multifactorial diseases
Bansal, Y., & Silakari, O. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.01.060 · Cited by 215
Phenotypic screening of the ToxCast chemical library to classify toxic and therapeutic mechanisms
Kleinstreuer, N. C., Yang, J., Berg, E. L., Knudsen, T. B., Richard, A. M., Martin, M. T., Reif, D. M., Judson, R. S., Polokoff, M., Dix, D. J., et al. (2014) · Nature Biotechnology · doi:10.1038/nbt.2914 · Cited by 211
Selective Optimization of Side Activities: Another Way for Drug Discovery
Wermuth, C. G. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm030480f · Cited by 209
Fragments, network biology and designing multiple ligands
Morphy, R., & Ranković, Z. (2006) · Drug Discovery Today · doi:10.1016/j.drudis.2006.12.006 · Cited by 206
Modern Phenotypic Drug Discovery Is a Viable, Neoclassic Pharma Strategy
Lee, J. A., Uhlik, M. T., Moxham, C. M., Tomandl, D., & Sall, D. J. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm201649s · Cited by 197
The Physicochemical Challenges of Designing Multiple Ligands
Morphy, R., & Ranković, Z. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm0603015 · Cited by 194
Metabolic effect of telmisartan and losartan in hypertensive patients with metabolic syndrome
Vitale, C., Mercuro, G. G., Castiglioni, C., Cornoldi, A., Tulli, A., Fini, M., Volterrani, M., & Rosano, G. M. C. (2005) · Cardiovascular Diabetology · doi:10.1186/1475-2840-4-6 · Cited by 193
Modeling Parkinson's Disease in Primates: The MPTP ModelPreprint
Porras, G., Li, Q., & Bézard, E. (2011) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a009308 · Cited by 190
Computational Multitarget Drug Design
Zhang, W., Pei, J., & Lai, L. (2017) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.6b00491 · Cited by 189
Development and Properties of β-Glucuronide Linkers for Monoclonal Antibody−Drug Conjugates
Jeffrey, S. C., Andreyka, J. B., Bernhardt, S. X., Kissler, K. M., Kline, T. B., Lenox, J. S., Moser, R. F., Nguyen, M. T., Okeley, N. M., Stone, I. J., et al. (2006) · Bioconjugate Chemistry · doi:10.1021/bc0600214 · Cited by 183
Multi-Target Directed Drugs: A Modern Approach for Design of New Drugs for the treatment of Alzheimer’s Disease
Dias, K. S. T., & Viegas, C. (2014) · Current Neuropharmacology · doi:10.2174/1570159x1203140511153200 · Cited by 178
Pharmacophore-Based Virtual Screening
Sun, H. (2008) · Current Medicinal Chemistry · doi:10.2174/092986708784049630 · Cited by 176
Structural Protein?Ligand Interaction Fingerprints (SPLIF) for Structure-Based Virtual Screening: Method and Benchmark Study
Da, C., & Kireev, D. (2014) · Journal of Chemical Information and Modeling · doi:10.1021/ci500319f · Cited by 174
Chemically Advanced Template Search (CATS) for Scaffold‐Hopping and Prospective Target Prediction for ‘Orphan’ Molecules
Reutlinger, M., Koch, C. P., Reker, D., Todoroff, N. K., Schneider, P., Rodrigues, T., & Schneider, G. (2013) · Molecular Informatics · doi:10.1002/minf.201200141 · Cited by 169
De Novo Design at the Edge of Chaos
Schneider, P., & Schneider, G. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01849 · Cited by 168
De Novo Drug Design
Hartenfeller, M., & Schneider, G. (2010) · Methods in molecular biology · doi:10.1007/978-1-60761-839-3_12 · Cited by 165
How to design multi-target drugs
Korcsmaros, T. D., Szalay, M., Böde, C., Kovács, I. A., & Csermely, P. (2007) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2.6.799 · Cited by 162
Multi-Target Directed Donepezil-Like Ligands for Alzheimer's Disease
Unzeta, M., Esteban, G., Bolea, I., Fogel, W. A., Ramsay, R. R., Youdim, M. B. H., Tipton, K. F., & Marco, J. L. (2016) · Frontiers in Neuroscience · doi:10.3389/fnins.2016.00205 · Cited by 154
Epigenetic polypharmacology: from combination therapy to multitargeted drugs
de Lera, Á. R., & Ganesan, A. (2016) · Clinical Epigenetics · doi:10.1186/s13148-016-0271-9 · Cited by 154
Hybrid Compounds as Direct Multitarget Ligands: A Review
Pedrosa, M. O., da Cruz, R. M. D., Viana, J. D. O., de Moura, R. O., Ishiki, H. M., Barbosa‐Filho, J. M., Diniz, M. D. F. F. M., Scotti, L., Scotti, L., & Mendonca, F. B. (2016) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026616666160927160620 · Cited by 154
A Synthetic Dual Drug Sideromycin Induces Gram-Negative Bacteria To Commit Suicide with a Gram-Positive Antibiotic
Liu, R., Miller, P. A., Vakulenko, S. B., Stewart, N. K., Boggess, B., & Miller, M. J. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00218 · Cited by 153
Scaffold-based discovery of indeglitazar, a PPAR pan-active anti-diabetic agent
Artis, D. R., Lin, J. J., Zhang, C., Wang, W., Mehra, U., Perreault, M., Erbe, D. V., Krupka, H. I., England, B. P., Arnold, J., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0811325106 · Cited by 150
Donepezil + propargylamine + 8-hydroxyquinoline hybrids as new multifunctional metal-chelators, ChE and MAO inhibitors for the potential treatment of Alzheimer's disease
Wang, L., Esteban, G., Ojima, M., Bautista‐Aguilera, Ó. M., Inokuchi, T., Moraleda, I., Iriepa, I., Samadi, A., Youdim, M. B. H., Romero, A., et al. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.04.078 · Cited by 143
Discovery of Multitarget Inhibitors by Combining Molecular Docking with Common Pharmacophore Matching
Wei, D., Jiang, X., Zhou, L., Chen, J., Chen, Z., He, C., Yang, K., Liu, Y., Pei, J., & Lai, L. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm8010096 · Cited by 141
Identification and structure elucidation of the pro‐resolving mediators provides novel leads for resolution pharmacology
Dalli, J., & Serhan, C. N. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14336 · Cited by 138
Inhibitors of the Arachidonic Acid Cascade: Interfering with Multiple Pathways
Meirer, K., Steinhilber, D., & Proschak, E. (2013) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.12134 · Cited by 137
Self-citation
Targeted Antibiotic Delivery: Selective Siderophore Conjugation with Daptomycin Confers Potent Activity against Multidrug Resistant Acinetobacter baumannii Both in Vitro and in Vivo
Ghosh, M., Miller, P. A., Möllmann, U., Claypool, W. D., Schroeder, V. A., Wolter, W. R., Suckow, M. A., Yu, H., Li, S., Huang, W., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00102 · Cited by 134
Liver-specific drug targeting by coupling to bile acids.
Kramer, W., Wess, G., Schubert, G., Bickel, M., Girbig, F., Gutjahr, U., Kowalewski, S., Baringhaus, K. H., Enhsen, A., & Glombik, H. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)37003-6 · Cited by 133
Trihydroxamate Siderophore–Fluoroquinolone Conjugates Are Selective Sideromycin Antibiotics that Target Staphylococcus aureus
Wencewicz, T. A., Long, T. E., Möllmann, U., & Miller, M. J. (2013) · Bioconjugate Chemistry · doi:10.1021/bc300610f · Cited by 132
Aripiprazole, A Drug that Displays Partial Agonism and Functional Selectivity
Tuplin, E. W. N., & Holahan, M. R. (2017) · Current Neuropharmacology · doi:10.2174/1570159x15666170413115754 · Cited by 131
Prediction of synergistic anti-cancer drug combinations based on drug target network and drug induced gene expression profiles
Li, X., Xu, Y., Cui, H. S., Huang, T., Wang, D., Lian, B., Li, W., Qin, G., Chen, L., & Xie, L. (2017) · Artificial Intelligence in Medicine · doi:10.1016/j.artmed.2017.05.008 · Cited by 128
Biscatecholate–Monohydroxamate Mixed Ligand Siderophore–Carbacephalosporin Conjugates are Selective Sideromycin Antibiotics that Target Acinetobacter baumannii
Wencewicz, T. A., & Miller, M. J. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400265k · Cited by 127
Harnessing synthetic lethality to predict the response to cancer treatment
Lee, J. S., Das, A., Jerby‐Arnon, L., Arafeh, R., Auslander, N., Davidson, M. A., McGarry, L., James, D. T., Amzallag, A., Park, S. G., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-04647-1 · Cited by 122
Comparative Analysis of Pharmacophore Screening Tools
Sanders, M. P. A., Barbosa, A. J. M., Zarzycka, B. A., Nicolaes, G. A. F., Klomp, J. P. G., de Vlieg, J., & Río, A. D. (2012) · Journal of Chemical Information and Modeling · doi:10.1021/ci2005274 · Cited by 118
Memoquin: A Multi-Target–Directed Ligand as an Innovative Therapeutic Opportunity for Alzheimer's Disease
Bolognesi, M. L., Cavalli, A., & Melchiorre, C. (2008) · Neurotherapeutics · doi:10.1016/j.nurt.2008.10.042 · Cited by 117
The role of fragment-based and computational methods in polypharmacology
Bottegoni, G., Favia, A. D., Recanatini, M., & Cavalli, A. (2011) · Drug Discovery Today · doi:10.1016/j.drudis.2011.08.002 · Cited by 116
Dynamic tuneable G protein-coupled receptor monomer-dimer populations
Dijkman, P. M., Castell, O. K., Goddard, A. D., Muñoz-García, J. C., de Graaf, C., Wallace, M. I., & Watts, A. G. (2018) · Nature Communications · doi:10.1038/s41467-018-03727-6 · Cited by 116
Dynamic Simulations on the Arachidonic Acid Metabolic Network
Yang, K., Ma, W., Liang, H., Ouyang, Q., Tang, C., & Lai, L. (2007) · PLoS Computational Biology · doi:10.1371/journal.pcbi.0030055 · Cited by 115
Synergy between Enzyme Inhibitors of Fatty Acid Amide Hydrolase and Cyclooxygenase in Visceral Nociception
Naidu, P. S., Booker, L., Cravatt, B. F., & Lichtman, A. H. (2009) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.108.143487 · Cited by 115
Strategies for modern biomarker and drug development in oncology
Smith, A. D., Roda, D., & Yap, T. A. (2014) · Journal of Hematology & Oncology · doi:10.1186/s13045-014-0070-8 · Cited by 112
Hitting multiple targets with multimeric ligands
Handl, H. L., Vágner, J., Han, H., Mash, E. A., Hruby, V. J., & Gillies, R. J. (2004) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.8.6.565 · Cited by 111
Hot-Spots-Guided Receptor-Based Pharmacophores (HS-Pharm): A Knowledge-Based Approach to Identify Ligand-Anchoring Atoms in Protein Cavities and Prioritize Structure-Based Pharmacophores
Barillari, C., Marcou, G., & Rognan, D. (2008) · Journal of Chemical Information and Modeling · doi:10.1021/ci800064z · Cited by 111
Navigating the Chemical Space of Multitarget-Directed Ligands: From Hybrids to Fragments in Alzheimer’s Disease
Prati, F., Cavalli, A., & Bolognesi, M. (2016) · Molecules · doi:10.3390/molecules21040466 · Cited by 110
Molecularly targeted drug combinations demonstrate selective effectiveness for myeloid- and lymphoid-derived hematologic malignancies
Kurtz, S. E., Eide, C. A., Kaempf, A. J., Khanna, V., Savage, S. L., Rofelty, A., English, I. A., Ho, H., Pandya, R., Bolosky, W. J., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1703094114 · Cited by 110
Statins: the new aspirin?
Veillard, N. R., & Mach, F. (2002) · Cellular and Molecular Life Sciences · doi:10.1007/pl00012505 · Cited by 107
Profiling Bioactivity of the ToxCast Chemical Library Using BioMAP Primary Human Cell Systems
Houck, K. A., Dix, D. J., Judson, R., Kavlock, R. J., Yang, J. B., & Berg, E. L. (2009) · SLAS DISCOVERY · doi:10.1177/1087057109345525 · Cited by 107
Drug discovery and development for rare genetic disorders
Sun, W., Zheng, W., & Simeonov, A. (2017) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.38326 · Cited by 107
Multitarget‐Directed Ligands Combining Cholinesterase and Monoamine Oxidase Inhibition with Histamine H3R Antagonism for Neurodegenerative Diseases
Bautista‐Aguilera, Ó. M., Hagenow, S., Palomino‐Antolin, A., Farré‐Alins, V., Ismaili, L., Joffrin, P., Jimeno, M. L., Soukup, O., Janočková, J., Kalinowsky, L., et al. (2017) · Angewandte Chemie International Edition · doi:10.1002/anie.201706072 · Cited by 105
Self-citation
High-Throughput Crystallography: Reliable and Efficient Identification of Fragment Hits
Schiebel, J., Krimmer, S. G., Röwer, K., Knörlein, A., Wang, X., Park, A. Y., Stieler, M., Ehrmann, F. R., Fu, K., Radeva, N., et al. (2016) · Structure · doi:10.1016/j.str.2016.06.010 · Cited by 101
Improving the efficacy-safety balance of polypharmacology in multi-target drug discovery
Ravikumar, B., & Aittokallio, T. A. (2017) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2018.1413089 · Cited by 101
The NEWLEAD program: a new method for the design of candidate structures from pharmacophoric hypotheses
Tschinke, V., & Cohen, N. C. (1993) · Journal of Medicinal Chemistry · doi:10.1021/jm00076a016 · Cited by 100
Polypharmacology in Precision Oncology: Current Applications and Future Prospects
Antolín, A. A., Workman, P., Mestres, J., & Al‐Lazikani, B. (2016) · Current Pharmaceutical Design · doi:10.2174/1381612822666160923115828 · Cited by 97
A Computational Approach for Identifying Synergistic Drug Combinations
Gayvert, K. M., Aly, O., Platt, J. T., Bosenberg, M., Stern, D. F., & Elemento, O. (2017) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1005308 · Cited by 97
Bitopic Ligands and Metastable Binding Sites: Opportunities for G Protein-Coupled Receptor (GPCR) Medicinal Chemistry
Fronik, P., Gaiser, B. I., & Pedersen, D. S. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01601 · Cited by 97
Multitarget drugs: the present and the future of cancer therapy
Petrelli, A., & Valabrega, G. (2009) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560902781907 · Cited by 93
Rationally Designed Multi-Targeted Agents Against Neurodegenerative Diseases
Geldenhuys, W. J., & der Schyf, C. J. V. (2013) · Current Medicinal Chemistry · doi:10.2174/09298673113209990112 · Cited by 93
One for All? Hitting Multiple Alzheimer's Disease Targets with One Drug
Hughes, R. E., Nikolic, K. M., & Ramsay, R. R. (2016) · Frontiers in Neuroscience · doi:10.3389/fnins.2016.00177 · Cited by 93
Orthosteric/Allosteric Bitopic Ligands: Going Hybrid at GPCRs
Valant, C., Sexton, P. M., & Christopoulos, A. (2009) · Molecular Interventions · doi:10.1124/mi.9.3.6 · Cited by 91
Kinase-likeness and Kinase-Privileged Fragments: Toward Virtual Polypharmacology
Aronov, A. M., McClain, B., Moody, C. S., & Murcko, M. A. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm701021b · Cited by 91
3-Benzisothiazolylpiperazine Derivatives as Potential Atypical Antipsychotic Agents
Howard, H. R., Lowe, J. A., III, Seeger, T., Seymour, P. A., Zorn, S. H., Maloney, P., Ewing, F. E., Newman, M. E., Schmidt, A. W., Furman, J. S., et al. (1996) · Journal of Medicinal Chemistry · doi:10.1021/jm950625l · Cited by 90
5-HT1 and 5-HT2: binding characteristics of some quipazine analogs
Glennon, R. A., Slusher, R. M., Lyon, R. A., Titeler, M., & MCKENNEY, J. D. J. (1986) · Journal of Medicinal Chemistry · doi:10.1021/jm00161a038 · Cited by 90
Opportunities and Challenges for Fatty Acid Mimetics in Drug Discovery
Proschak, E., Heitel, P., Kalinowsky, L., & Merk, D. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01287 · Cited by 90
Self-citation
Cefiderocol: a novel siderophore cephalosporin
Choi, J. J., & McCarthy, M. W. (2018) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2018.1426745 · Cited by 88
A Dual Modulator of Farnesoid X Receptor and Soluble Epoxide Hydrolase To Counter Nonalcoholic Steatohepatitis
Schmidt, J., Rotter, M., Weiser, T., Wittmann, S. K., Weizel, L., Kaiser, A., Heering, J., Goebel, T., Angioni, C., Wurglics, M., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00398 · Cited by 87
Self-citation
Drug synergy screen and network modeling in dedifferentiated liposarcoma identifies CDK4 and IGF1R as synergistic drug targets
Miller, M. L., Molinelli, E. J., Nair, J. S., Sheikh, T., Samy, R., Jing, X., He, Q., Korkut, A., Crago, A. M., Singer, S., et al. (2013) · Science Signaling · doi:10.1126/scisignal.2004014 · Cited by 86
In defence of polypharmacy
Aronson, J. K. (2004) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2004.02067.x · Cited by 85
Cardioprotection by Metformin: Beneficial Effects Beyond Glucose Reduction
Varjabedian, L., Bourji, M., Pourafkari, L., & Nader, N. D. (2018) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-018-0266-3 · Cited by 85
Experimental Models of Parkinson's Disease: From the Static to the Dynamic
Bézard, E., Imbert, C., & Gross, C. E. (1998) · Reviews in the Neurosciences · doi:10.1515/revneuro.1998.9.2.71 · Cited by 83
Multivalent Ligand: Design Principle for Targeted Therapeutic Delivery Approach
Chittasupho, C. (2012) · Therapeutic Delivery · doi:10.4155/tde.12.99 · Cited by 81
Quantification of Pathway Cross-talk Reveals Novel Synergistic Drug Combinations for Breast Cancer
Jaeger, S., Igea, A., Arroyo, R., Alcalde, V., Cánovas, B., Orozco, M., Nebreda, Á. R., & Aloy, P. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0097 · Cited by 81
Dual Aromatase−Steroid Sulfatase Inhibitors
Woo, L. W. L., Bubert, C., Sutcliffe, O. B., Smith, A., Chander, S. K., Mahon, M. F., Purohit, A., Reed, M. J., & Potter, B. V. L. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm061462b · Cited by 80
The effectiveness of multi-target agents in schizophrenia and mood disorders: Relevance of receptor signature to clinical action
Wong, E. H. F., Tarazi, F. I., & Shahid, M. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2010.02.001 · Cited by 78
Key Targets for Multi-Target Ligands Designed to Combat Neurodegeneration
Ramsay, R. R., Májeková, M., Medina, M., & Valoti, M. (2016) · Frontiers in Neuroscience · doi:10.3389/fnins.2016.00375 · Cited by 76
Predicting Drug Combination Index and Simulating the Network-Regulation Dynamics by Mathematical Modeling of Drug-Targeted EGFR-ERK Signaling Pathway
Huang, L., Jiang, Y., & Chen, Y. (2017) · Scientific Reports · doi:10.1038/srep40752 · Cited by 76
The use of natural compounds for the targeting and chemoprevention of ovarian cancer
Pistollato, F., Iglesias, R. C., Ruíz, R., Obregón, S. A., Crespo, J., López, L. A. D., Giampieri, F., & Battino, M. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.09.050 · Cited by 76
Acid-cleavable thiomaleamic acid linker for homogeneous antibody–drug conjugation
Castañeda, L., Maruani, A., Schumacher, F. F., Miranda, E., Chudasama, V., Chester, K. A., Baker, J. R., Smith, M. E. B., & Caddick, S. (2013) · Chemical Communications · doi:10.1039/c3cc45220d · Cited by 74
Drug Repurposing and the Medicinal Chemist
Aubé, J. (2012) · ACS Medicinal Chemistry Letters · doi:10.1021/ml300114c · Cited by 73
Potential of immunomodulatory agents as adjunct host-directed therapies for multidrug-resistant tuberculosis
Zumla, A. I., Rao, M., Dodoo, E., & Maeurer, M. J. (2016) · BMC Medicine · doi:10.1186/s12916-016-0635-1 · Cited by 73
Development of a New Class of Nonimidazole Histamine H3 Receptor Ligands with Combined Inhibitory Histamine N-Methyltransferase Activity
Apelt, J., Ligneau, X., Pertz, H. H., Arrang, J., Ganellin, C. R., Schwartz, J., Schunack, W. G., & Stark, H. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm0110845 · Cited by 71
Self-citation
Target Fishing for Chemical Compounds Using Target-Ligand Activity Data and Ranking Based Methods
Wale, N., & Karypis, G. (2009) · Journal of Chemical Information and Modeling · doi:10.1021/ci9000376 · Cited by 71
Designed Multiple Ligands: Basic Research vs Clinical Outcomes
Costantino, L., & Barlocco, D. (2012) · Current Medicinal Chemistry · doi:10.2174/092986712801215883 · Cited by 69
Polypharmacology of dopamine receptor ligands
Butini, S., Nikolic, K. M., Kassel, S., Brückmann, H., Filipić, S., Agbaba, D. D., Gemma, S., Brogi, S., Brindisi, M., Campiani, G., et al. (2016) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2016.03.011 · Cited by 69
Self-citation
3,4-Dihydro-1,3,5-triazin-2(1H)-ones as the First Dual BACE-1/GSK-3β Fragment Hits against Alzheimer’s Disease
Prati, F., Simone, A. D., Armirotti, A., Summa, M., Pizzirani, D., Scarpelli, R., Bertozzi, S. M., Pérez, D. I., Andrisano, V., Pérez‐Castillo, A., et al. (2015) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.5b00121 · Cited by 68
De Novo Design of Multitarget Ligands with an Iterative Fragment-Growing Strategy
Shang, E., Yuan, Y., Chen, X., Liu, Y., Pei, J., & Lai, L. (2014) · Journal of Chemical Information and Modeling · doi:10.1021/ci500021v · Cited by 68
Structure–Activity Relationships and Computational Investigations into the Development of Potent and Balanced Dual-Acting Butyrylcholinesterase Inhibitors and Human Cannabinoid Receptor 2 Ligands with Pro-Cognitive in Vivo Profiles
Dolles, D., Hoffmann, M., Gunesch, S., Marinelli, O., Möller, J., Santoni, G., Chatonnet, A., Lohse, M. J., Wittmann, H.-J., Strasser, A., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01760 · Cited by 67
Designed Multiple Ligands: An Emerging Anti-HIV Drug Discovery Paradigm
Zhan, P., & Liu, X. (2009) · Current Pharmaceutical Design · doi:10.2174/138161209788453266 · Cited by 66
Rational Polypharmacology: Systematically Identifying and Engaging Multiple Drug Targets To Promote Axon Growth
Al‐Ali, H., Lee, D.-H., Danzi, M. C., Nassif, H., Gautam, P., Wennerberg, K., Zuercher, B., Drewry, D. H., Lee, J. K., Lemmon, V., et al. (2015) · ACS Chemical Biology · doi:10.1021/acschembio.5b00289 · Cited by 66
Targets Looking for Drugs: A Multistep Computational Protocol for the Development of Structure-Based Pharmacophores and Their Applications for Hit Discovery
Tintori, C., Corradi, V., Magnani, M., Manetti, F., & Botta, M. (2008) · Journal of Chemical Information and Modeling · doi:10.1021/ci800105p · Cited by 65
Aromatase and Dual Aromatase‐Steroid Sulfatase Inhibitors from the Letrozole and Vorozole Templates
Wood, P. M., Woo, L. W. L., THOMAS, M. P., Mahon, M. F., Purohit, A., & Potter, B. V. L. (2011) · ChemMedChem · doi:10.1002/cmdc.201100145 · Cited by 64
Multitarget ligands in antibacterial research: progress and opportunities
East, S. P., & Silver, L. L. (2012) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2013.743991 · Cited by 64
New Insights Into the Anti-Diabetic Actions of Metformin: From the Liver to the Gut
Wu, T., Horowitz, M., & Rayner, C. K. (2017) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2017.1273769 · Cited by 64
Serotonin, β‐amyloid, and cognition in Parkinson disease
Kotagal, V., Spino, C., Bohnen, N. I., Koeppe, R., & Albin, R. L. (2018) · Annals of Neurology · doi:10.1002/ana.25236 · Cited by 64
High-throughput identification and rational design of synergistic small-molecule pairs for combating and bypassing antibiotic resistance
Wambaugh, M. A., Shakya, V. P. S., Lewis, A. J., Mulvey, M. A., & Brown, J. C. S. (2017) · PLOS Biology · doi:10.1371/journal.pbio.2001644 · Cited by 63
A whole-animal platform to advance a clinical kinase inhibitor into new disease space
Sonoshita, M., Scopton, A. P., Ung, P. M. U., Murray, M. A., Silber, L., Maldonado, A. Y., Real, A. M., Schlessinger, A., Cagan, R. L., & Dar, A. C. (2018) · Nature Chemical Biology · doi:10.1038/nchembio.2556 · Cited by 63
Soluble epoxide hydrolase inhibition and peroxisome proliferator activated receptor γ agonist improve vascular function and decrease renal injury in hypertensive obese rats
Imig, J. D., Walsh, K., Khan, A. H., Nagasawa, T., Shaw, M. C., Shaw, S. M., & Hammock, B. D. (2012) · Experimental Biology and Medicine · doi:10.1258/ebm.2012.012225 · Cited by 60
The story of antipsychotics: Past and present
Ramachandraiah, C., Subramaniam, N., & Tancer, M. E. (2009) · Indian Journal of Psychiatry · doi:10.4103/0019-5545.58304 · Cited by 60
Serendipity in Cancer Drug Discovery: Rational or Coincidence?
Prasad, S., Gupta, S. C., & Aggarwal, B. B. (2016) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2016.03.004 · Cited by 59
The Human Kinome Targeted by FDA Approved Multi-Target Drugs and Combination Products: A Comparative Study from the Drug-Target Interaction Network Perspective
Li, Y., Wang, P., Li, X. X., Yu, C. Y., Yang, H. J., Zhou, J., Xue, W., Tan, J., & Zhu, F. (2016) · PLoS ONE · doi:10.1371/journal.pone.0165737 · Cited by 59
Co-targeting cancer drug escape pathways confers clinical advantage for multi-target anticancer drugs
Tao, L., Zhu, F., Xu, F., Chen, Z., Jiang, Y., & Chen, Y. (2015) · Pharmacological Research · doi:10.1016/j.phrs.2015.09.019 · Cited by 56
Small molecules with anti-inflammatory properties in clinical development
Hanke, T., Merk, D., Steinhilber, D., Geißlinger, G., & Schubert‐Zsilavecz, M. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.11.011 · Cited by 54
Self-citation
Multi-target therapeutics for neuropsychiatric and neurodegenerative disorders
Bawa, P., Pradeep, P., Kumar, P., Choonara, Y. E., Modi, G., & Pillay, V. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.08.001 · Cited by 54
Discovery of a Series of Imidazo[4,5-b]pyridines with Dual Activity at Angiotensin II Type 1 Receptor and Peroxisome Proliferator-Activated Receptor-γ
Casimiro‐Garcia, A., Filzen, G. F., Flynn, D. A., Bigge, C. F., Chen, J., Davis, J. A., Dudley, D. A., Edmunds, J. J., Esmaeil, N., Geyer, A. G., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm200409s · Cited by 53
1-Naphthylpiperazine derivatives as potential atypical antipsychotic agents
Lowe, J. A., III, Seeger, T., Nagel, A. A., Howard, H. R., Seymour, P. A., Heym, J. H., Ewing, F. E., Newman, M. E., & Schmidt, A. W. (1991) · Journal of Medicinal Chemistry · doi:10.1021/jm00110a016 · Cited by 53
N -Benzylbenzamides: A Novel Merged Scaffold for Orally Available Dual Soluble Epoxide Hydrolase/Peroxisome Proliferator-Activated Receptor γ Modulators
Blöcher, R., Lamers, C., Wittmann, S. K., Merk, D., Hartmann, M., Weizel, L., Diehl, O., Brüggerhoff, A., Boß, M., Kaiser, A., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01239 · Cited by 53
Self-citation
High-content screening of small compounds on human embryonic stem cells.
Barbaric, I., Gokhale, P., & Andrews, P. (2010) · Biochemical Society Transactions · doi:10.1042/bst0381046 · Cited by 52
Prediction of Antibiotic Interactions Using Descriptors Derived from Molecular Structure
Mason, D. J., Stott, I. P., Ashenden, S. K., Weinstein, Z., Karakoc, I., Meral, S., Kuru, N., Bender, A., & Cokol, M. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00204 · Cited by 52
The pleiotropic functions of aspirin: mechanisms of action
Amin, A. R., Attur, M. G., Pillinger, M. H., & Abramson, S. B. (1999) · Cellular and Molecular Life Sciences · doi:10.1007/s000180050432 · Cited by 51
An Innovative Strategy for Dual Inhibitor Design and Its Application in Dual Inhibition of Human Thymidylate Synthase and Dihydrofolate Reductase Enzymes
Arooj, M., Sakkiah, S., Cao, G. P., & Lee, K. W. (2013) · PLoS ONE · doi:10.1371/journal.pone.0060470 · Cited by 51
Advances in computational approaches in identifying synergistic drug combinations
Sheng, Z., Sun, Y., Yin, Z., Tang, K., & Cao, Z. (2017) · Briefings in Bioinformatics · doi:10.1093/bib/bbx047 · Cited by 50
Dual-Target Virtual Screening by Pharmacophore Elucidation and Molecular Shape Filtering
Moser, D. M., Wisniewska, J. M., Hahn, S., Achenbach, J., Buscató, E., Klingler, F., Hofmann, B., Steinhilber, D., & Proschak, E. (2012) · ACS Medicinal Chemistry Letters · doi:10.1021/ml200286e · Cited by 49
Self-citation
Polypharmacology in Drug Discovery
Peters, J. (2012) · Wiley eBooks · doi:10.1002/9781118098141 · Cited by 49
Experimental animal models of Parkinson's disease: A transition from assessing symptomatology to α-synuclein targeted disease modification
Ko, W. K. D., & Bézard, E. (2017) · Experimental Neurology · doi:10.1016/j.expneurol.2017.07.020 · Cited by 48
Effects of Aspirin on Endothelial Function and Hypertension
Dzeshka, M. S., Shantsila, A., & Lip, G. Y. H. (2016) · Current Hypertension Reports · doi:10.1007/s11906-016-0688-8 · Cited by 47
Serotonergic Approaches in Parkinson’s Disease: Translational Perspectives, an Update
Huot, P., Sgambato, V., Fox, S. H., & McCreary, A. C. (2017) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.6b00440 · Cited by 47
Synthesis of bile acid - drug conjugates: Potential drug - shuttles for liver specific targeting
Wess, G., Kramer, W., Schubert, G., Enhsen, A., Baringhaus, K. H., Glombik, H., Müllner, S., Bock, K., Kleine, H. P., John, M., et al. (1993) · Tetrahedron Letters · doi:10.1016/0040-4039(93)89021-h · Cited by 45
Characterization of New PPARγ Agonists: Analysis of Telmisartan’s Structural Components
Goebel, M., Clemenz, M., Staels, B., Unger, T., Kintscher, U., & Gust, R. (2009) · ChemMedChem · doi:10.1002/cmdc.200800285 · Cited by 45
Accessing target information by virtual parallel screening—The impact on natural product research
Rollinger, J. M. (2008) · Phytochemistry Letters · doi:10.1016/j.phytol.2008.12.002 · Cited by 45
Fragment‐Based Discovery of a Dual pan‐RET/VEGFR2 Kinase Inhibitor Optimized for Single‐Agent Polypharmacology
Frett, B., Carlomagno, F., Moccia, M. L., Brescia, A., Federico, G., Falco, V. D., Admire, B., Chen, Z., Qi, W., Santoro, M. M., et al. (2015) · Angewandte Chemie International Edition · doi:10.1002/anie.201501104 · Cited by 45
Network Analysis of Drug–target Interactions: A Study on FDA-approved New Molecular Entities Between 2000 to 2015
Lin, H.-H., Zhang, L., Yan, R., Lu, J., & Yuanjia, H. (2017) · Scientific Reports · doi:10.1038/s41598-017-12061-8 · Cited by 45
The Chemical Design and Synthesis of Linkers Used in Antibody Drug Conjugates
Frigerio, M., & Kyle, A. F. (2018) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026618666180118155847 · Cited by 45
ADME and Safety Aspects of Non-cleavable Linkers in Drug Discovery and Development
Walles, M., Connor, A., & Hainzl, D. (2018) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026618666180118153502 · Cited by 45
A novel interaction fingerprint derived from per atom score contributions: exhaustive evaluation of interaction fingerprint performance in docking based virtual screening
Jasper, J., Humbeck, L., Brinkjost, T., & Koch, O. (2018) · Journal of Cheminformatics · doi:10.1186/s13321-018-0264-0 · Cited by 44
A novel dual PPAR-γ agonist/sEH inhibitor treats diabetic complications in a rat model of type 2 diabetes
Khan, A. H., Kolb, L. L., Skibba, M. E., Hartmann, M., Blöcher, R., Proschak, E., & Imig, J. D. (2018) · Diabetologia · doi:10.1007/s00125-018-4685-0 · Cited by 44
Self-citation
Use of biomarkers in ALS drug development and clinical trials
Bakkar, N., Boehringer, A. V., & Bowser, R. P. (2014) · Brain Research · doi:10.1016/j.brainres.2014.10.031 · Cited by 43
Dynamic eicosanoid responses upon different inhibitor and combination treatments on the arachidonic acid metabolic network
He, C., Wu, Y., Lai, Y., Cai, Z., Liu, Y., & Lai, L. (2012) · Molecular BioSystems · doi:10.1039/c2mb05503a · Cited by 43
A Quantitative Chemotherapy Genetic Interaction Map Reveals Factors Associated with PARP Inhibitor Resistance
Hu, H., Zhao, X., Kaushik, S., Robillard, L., Barthelet, A., Lin, K., Shah, K. N., Simmons, A. D., Raponi, M., Harding, T. C., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.03.093 · Cited by 42
Leveraging Large-scale Behavioral Profiling in Zebrafish to Explore Neuroactive Polypharmacology
McCarroll, M. N., Gendelev, L., Keiser, M. J., & Kokel, D. (2016) · ACS Chemical Biology · doi:10.1021/acschembio.5b00800 · Cited by 41
Targeting Epigenetic Networks with Polypharmacology: A New Avenue to Tackle Cancer
Franci, G., Miceli, M., & Altucci, L. (2010) · Epigenomics · doi:10.2217/epi.10.62 · Cited by 40
The dual-acting H3 receptor antagonist and AChE inhibitor UW-MD-71 dose-dependently enhances memory retrieval and reverses dizocilpine-induced memory impairment in rats
Khan, N., Saad, A. K., Nurulain, S. M., Darras, F. H., Decker, M. W., & Sadek, B. S. (2015) · Behavioural Brain Research · doi:10.1016/j.bbr.2015.10.022 · Cited by 40
Telmisartan Improves Insulin Resistance: A Meta-Analysis
Wang, Y., Qiao, S., De-wu, H., Rong, X.-R., Wang, Y.-X., Xue, J., & Yang, J. (2018) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000000733 · Cited by 40
Hybrid Dual Aromatase-Steroid Sulfatase Inhibitors with Exquisite Picomolar Inhibitory Activity
Woo, L. W. L., Bubert, C., Purohit, A., & Potter, B. V. L. (2010) · ACS Medicinal Chemistry Letters · doi:10.1021/ml100273k · Cited by 39
Exploring the Chemical Space of Multitarget Ligands Using Aligned Self-Organizing Maps
Achenbach, J., Klingler, F., Blöcher, R., Moser, D. M., Häfner, A., Rödl, C. B., Kretschmer, S. B. M., Krüger, B., Löhr, F., Stark, H., et al. (2013) · ACS Medicinal Chemistry Letters · doi:10.1021/ml4002562 · Cited by 38
Self-citation
Predicting synergistic effects between compounds through their structural similarity and effects on transcriptomes
Liu, Y., & Zhao, H. (2016) · Bioinformatics · doi:10.1093/bioinformatics/btw509 · Cited by 38

Research works printed but not linked: 1

Glen R. C., 2006, IDrugs, 9, 199

Sorted by citations

Artificial intelligence to deep learning: machine intelligence approach for drug discovery
Gupta, R., Srivastava, D., Sahu, M., Tiwari, S., Ambasta, R. K., & Kumar, P. (2021) · Molecular Diversity · doi:10.1007/s11030-021-10217-3 · Cited by 1,473
“It is best suited for designing a promising therapeutic agent for more complex diseases such as cancer, neurodegenerative disease (NDDs), diabetes, heart failure, and many others [353–355].”
Background
Towards the sustainable discovery and development of new antibiotics
Miethke, M., Pieroni, M., Weber, T., Brönstrup, M., Hammann, P., Halby, L., Arimondo, P. B., Glaser, P., Aigle, B., Bode, H. B., et al. (2021) · Nature Reviews Chemistry · doi:10.1038/s41570-021-00313-1 · Cited by 1,228
RNA-Based Therapeutics: From Antisense Oligonucleotides to miRNAs
Bajan, S., & Hutvágner, G. (2020) · Cells · doi:10.3390/cells9010137 · Cited by 409
Image-based profiling for drug discovery: due for a machine-learning upgrade?
Chandrasekaran, S. N., Ceulemans, H., Boyd, J. D., & Carpenter, A. E. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-00117-w · Cited by 407
Phenotypic drug discovery: recent successes, lessons learned and new directions
Vincent, F., Nueda, A., Lee, J. L. C., Schenone, M., Prunotto, M., & Mercola, M. A. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00472-w · Cited by 397

See all 555

Authors: Proschak, E., Stark, H., & Merk, D.
Affiliations: Goethe University Frankfurt (DE)
Heinrich Heine University Düsseldorf (DE)
Corresponding author: Merk, Daniel
ORCID: Proschak, Ewgenij
Stark, Holger
Merk, Daniel
Venue: Journal of Medicinal Chemistry
Publisher: American Chemical Society (ACS)
Published: 2018-07-23
Volume: 62
Issue: 2
Pages: 420-444
ISSN: 0022-2623 (ISSN-L)
1520-4804
DOI: 10.1021/acs.jmedchem.8b00760
OpenAlex: W2884740260
Cited by: 498
References: 251
Citations by year: 2026: 51 · 2025: 56 · 2024: 74 · 2023: 60 · 2022: 86 · 2021: 64 · 2020: 67 · 2019: 39 · 2018: 1
FWCI: 35.15
Type: journal article
Language: en
Open access: closed
Locations: Journal of Medicinal Chemistry (publishedVersion)
PubMed (publishedVersion)
Publikationsdatenbank der Fraunhofer-Gesellschaft (Fraunhofer-Gesellschaft) (submittedVersion)
Fraunhofer-Publica (Fraunhofer-Gesellschaft) (submittedVersion)
Funders: Eidgen?ssische Technische Hochschule Z?rich (16-2 FEL-07)
Deutsche Forschungsgemeinschaft (SFB1039, PR1405/2-2, PR1405/4-1)
European Cooperation in Science and Technology (CA15135)
Topics: Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
Physical Sciences › Chemistry › Organic Chemistry › Heterocyclic Compound Synthesis and Bioactivity
Keywords: polypharmacology, multi-target drug design, drug discovery, chemical probes, fragment-based design, crystallography, computer-aided drug design, complex diseases, drug synergy, side effect reduction
MeSH terms: Machine Learning, Animals, Chemistry, Pharmaceutical, Humans, Ligands, Structure-Activity Relationship, Drug Design, Crystallography, X-Ray, Models, Animal, Metabolic Networks and Pathways

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Polypharmacology by Design: A Medicinal Chemist’s Perspective on Multitargeting Compounds

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks